NDC 51144-020

PADCEV EJFV

Enfortumab Vedotin

PADCEV EJFV is a Intravenous Injection, Powder, Lyophilized, For Solution in the Human Prescription Drug category. It is labeled and distributed by Seagen Inc.. The primary component is Enfortumab Vedotin.

• Product ID: 51144-020_0e6ab7c8-66e2-4f5e-b93e-b1e3d59ab859
• NDC: 51144-020
• Product Type: Human Prescription Drug
• Proprietary Name: PADCEV EJFV
• Generic Name: Enfortumab Vedotin
• Dosage Form: Injection, Powder, Lyophilized, For Solution
• Route of Administration: INTRAVENOUS
• Marketing Start Date: 2019-12-18
• Marketing Category: BLA / BLA
• Application Number: BLA761137
• Labeler Name: SEAGEN INC.
• Substance Name: ENFORTUMAB VEDOTIN
• Active Ingredient Strength: 20 mg/2mL
• NDC Exclude Flag: N
• Listing Certified Through: 2022-12-31

Packaging

NDC 51144-020-01

1 VIAL, SINGLE-DOSE in 1 BOX (51144-020-01) > 2 mL in 1 VIAL, SINGLE-DOSE

• Marketing Start Date: 2019-12-18
• NDC Exclude Flag: N
• Sample Package?: N

NDC SPL Data Element Entries

NDC 51144-020-01 [51144002001]

PADCEV EJFV INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION

• Marketing Category: BLA
• Application Number: BLA761137
• Product Type: HUMAN PRESCRIPTION DRUG
• Billing Unit: EA
• Marketing Start Date: 2019-12-18

Drug Details

Active Ingredients

Ingredient	Strength
ENFORTUMAB VEDOTIN	20 mg/2.3mL

NDC Crossover Matching brand name "PADCEV EJFV" or generic name "Enfortumab Vedotin"

NDC	Brand Name	Generic Name
51144-020	PADCEV	ENFORTUMAB VEDOTIN
51144-030	PADCEV	ENFORTUMAB VEDOTIN